Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director | 16.89M | -- | 1959 |
| Mr. Chig Fung Cheng BEc, CA | CFO & Executive Director | 7.5M | -- | 1967 |
| Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E | Company Secretary & Non-Executive Director | -- | -- | 1952 |
| Ms. Yiling Cui | Executive VP & Head of Operations | -- | -- | -- |
| David Ng | Head of Investor Relations & Capital Strategies | -- | -- | -- |
| Mr. Charles George Rupert Nixon | Group General Counsel | -- | -- | 1970 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | -- | -- | 1977 |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | -- | -- | -- |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | -- | -- | 1963 |
| Dr. Zhenping Wu M.B.A, Ph.D. | Executive Vice President of Pharmaceutical Science & Manufacturing | -- | -- | 1959 |
HUTCHMED
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,811
Description
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Corporate Governance
Upcoming Events
March 19, 2025 at 11:00 AM UTC
HUTCHMED Earnings Date
Recent Events
Recent Events Information Not Available